Acelyrin, Inc. (SLRN) Tops Q2 EPS by 22c

Acelyrin, Inc. (NASDAQ: SLRN) reported Q2 EPS of ($0.86), $0.22 better than the analyst estimate of ($1.08).

For earnings history and earnings-related data on Acelyrin, Inc. (SLRN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Tencent Holdings (700:HK) (TCEHY) PT Lowered to HK$625 at Benchmark to Reflect Downward Earnings Revisions
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c